T11TS Inhibits Glioma Angiogenesis by Modulation of MMPs, TIMPs, with Related Integrin αv and TGF-β1 Expressions

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2013 Nov 19

PMID 24242015

Citations 7

Authors

Manoj Kumar Singh

Debanjan Bhattacharya

Suhnrita Chaudhuri

Sagar Acharya

Pankaj Kumar

Pranjal Santra

Anjan Kumar Basu

Swapna Chaudhuri

Affiliations

Soon will be listed here.

Abstract

During glioma development, angiogenesis plays a crucial role in growth and vascularization of primary brain tumors. T11 target structure (T11TS), a bioactive molecule, has been documented as an anti-neoplastic agent in glioma-induced rats and also in human glioma in vitro. This novel molecule induces apoptosis of tumor cells by way of immune potentiation and impairs the glioma cell cycle, but its role in glioma angiogenesis has not been worked out in detail. Matrix metalloproteinases (MMPs) are enzymes promoting tumor angiogenesis by enzymatically remodeling the extracellular matrix and altering surface protein expression such as integrin αv and the matrix-bound proteins like TGF-β1. The present study was formulated to assess the efficacy of T11TS in the modulations of MMP-2 and -9 and their endogenous inhibitors (TIMP-1 and TIMP-2) as well as modulations of integrin αv and TGF-β1 in glioma-induced rats and also on the phenotypic markers of endothelial cells (CD31 and CD34). The parameters used were zymography, western blot, and flow cytometric analyses. It was observed that T11TS administration significantly downregulates the expression of matrix metalloproteinase-2 and -9 along with its ligand integrin αv and upregulates TIMP-1 and TIMP-2. In situ immunofluorescence and FACS results revealed that T11TS administration decreased the expression of the phenotypic markers (CD31/PECAM1, CD34), inhibiting the cell grip and also downregulating TGF-β1 expression (ELISA) from microglia cells in the glioma microenvironment. These results suggest that T11TS suppresses the expression of positive angiogenic growth factors and potentiates the expression of negative regulators in glioma-associated endothelial cells (ECs), resulting in an anti-angiogenic effect on glioma-induced angiogenesis.

Citing Articles

Glioma-associated microglia/macrophages (GAMs) in glioblastoma: Immune function in the tumor microenvironment and implications for immunotherapy.

Lin C, Wang N, Xu C Front Immunol. 2023; 14:1123853.

PMID: 36969167 PMC: 10034134. DOI: 10.3389/fimmu.2023.1123853.

Prediction and analysis of hub genes between glioblastoma and low-grade glioma using bioinformatics analysis.

Xu B Medicine (Baltimore). 2021; 100(3):e23513.

PMID: 33545929 PMC: 7837950. DOI: 10.1097/MD.0000000000023513.

Angiogenesis: Managing the Culprits behind Tumorigenesis and Metastasis.

Yehya A, Asif M, Petersen S, Subramaniam A, Kono K, Majid A Medicina (Kaunas). 2018; 54(1).

PMID: 30344239 PMC: 6037250. DOI: 10.3390/medicina54010008.

Advances in immunotherapy for the treatment of glioblastoma.

Tivnan A, Heilinger T, Lavelle E, Prehn J J Neurooncol. 2016; 131(1):1-9.

PMID: 27743144 PMC: 5258809. DOI: 10.1007/s11060-016-2299-2.

Radix puerariae extracts ameliorate paraquat-induced pulmonary fibrosis by attenuating follistatin-like 1 and nuclear factor erythroid 2p45-related factor-2 signalling pathways through downregulation of miRNA-21 expression.

Liu M, Liu R, Wu H, Li Y, Su M, Dong M BMC Complement Altern Med. 2016; 16:11.

PMID: 26758514 PMC: 4711072. DOI: 10.1186/s12906-016-0991-6.

References

Davies B, Miles D, Happerfield L, Naylor M, Bobrow L, Rubens R . Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer. 1993; 67(5):1126-31. PMC: 1968428. DOI: 10.1038/bjc.1993.207. View

Baker A, Edwards D, Murphy G . Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci. 2002; 115(Pt 19):3719-27. DOI: 10.1242/jcs.00063. View

Bergers G, Brekken R, McMahon G, Vu T, Itoh T, Tamaki K . Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000; 2(10):737-44. PMC: 2852586. DOI: 10.1038/35036374. View

Fridman R, Toth M, Pena D, Mobashery S . Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res. 1995; 55(12):2548-55. View

Fransvea E, Mazzocca A, Antonaci S, Giannelli G . Targeting transforming growth factor (TGF)-betaRI inhibits activation of beta1 integrin and blocks vascular invasion in hepatocellular carcinoma. Hepatology. 2008; 49(3):839-50. DOI: 10.1002/hep.22731. View

Mukherjee J, Sarkar S, Ghosh A, Duttagupta A, Chaudhuri S, Chaudhuri S . Immunotherapeutic effects of T11TS/S-LFA3 against nitrosocompound mediated neural genotoxicity. Toxicol Lett. 2004; 150(3):239-57. DOI: 10.1016/j.toxlet.2004.01.016. View

Brooks P, Clark R, Cheresh D . Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994; 264(5158):569-71. DOI: 10.1126/science.7512751. View

Bhattacharjee M, Acharya S, Ghosh A, Sarkar P, Chatterjee S, Kumar P . Bax and Bid act in synergy to bring about T11TS-mediated glioma apoptosis via the release of mitochondrial cytochrome c and subsequent caspase activation. Int Immunol. 2008; 20(12):1489-505. DOI: 10.1093/intimm/dxn109. View

Silletti S, Kessler T, Goldberg J, Boger D, Cheresh D . Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc Natl Acad Sci U S A. 2001; 98(1):119-24. PMC: 14554. DOI: 10.1073/pnas.98.1.119. View

10.

Seo D, Li H, Guedez L, Wingfield P, Diaz T, Salloum R . TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell. 2003; 114(2):171-80. DOI: 10.1016/s0092-8674(03)00551-8. View

11.

Bhattacharya D, Singh M, Chaudhuri S, Acharya S, Basu A, Chaudhuri S . T11TS impedes glioma angiogenesis by inhibiting VEGF signaling and pro-survival PI3K/Akt/eNOS pathway with concomitant upregulation of PTEN in brain endothelial cells. J Neurooncol. 2013; 113(1):13-25. DOI: 10.1007/s11060-013-1095-5. View

12.

Gladson C . Expression of integrin alpha v beta 3 in small blood vessels of glioblastoma tumors. J Neuropathol Exp Neurol. 1996; 55(11):1143-9. DOI: 10.1097/00005072-199611000-00005. View

13.

Sarkar S, Begum Z, Dutta S, Dutta S, Chaudhuri S, Chaudhuri S . Sheep form of leucocyte function antigen-3 (T11TS) exerts immunostimulatory and anti-tumor activity against experimental brain tumor. A new approach to biological response modifier therapy. J Exp Clin Cancer Res. 2002; 21(1):95-106. View

14.

Eliceiri B, Cheresh D . Adhesion events in angiogenesis. Curr Opin Cell Biol. 2001; 13(5):563-8. DOI: 10.1016/s0955-0674(00)00252-0. View

15.

Seftor R, Seftor E, Stetler-Stevenson W, Hendrix M . The 72 kDa type IV collagenase is modulated via differential expression of alpha v beta 3 and alpha 5 beta 1 integrins during human melanoma cell invasion. Cancer Res. 1993; 53(14):3411-5. View

16.

Brenner C, Adler R, Rappolee D, Pedersen R, Werb Z . Genes for extracellular-matrix-degrading metalloproteinases and their inhibitor, TIMP, are expressed during early mammalian development. Genes Dev. 1989; 3(6):848-59. DOI: 10.1101/gad.3.6.848. View

17.

Tokuraku M, Sato H, Murakami S, Okada Y, Watanabe Y, Seiki M . Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastasis. Int J Cancer. 1995; 64(5):355-9. DOI: 10.1002/ijc.2910640513. View

18.

Liotta L, Tryggvason K, Garbisa S, Hart I, FOLTZ C, Shafie S . Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature. 1980; 284(5751):67-8. DOI: 10.1038/284067a0. View

19.

Felding-Habermann B, OToole T, Smith J, Fransvea E, Ruggeri Z, Ginsberg M . Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci U S A. 2001; 98(4):1853-8. PMC: 29346. DOI: 10.1073/pnas.98.4.1853. View

20.

Oehring R, Miletic M, Valter M, Pietsch T, Neumann J, Fimmers R . Vascular endothelial growth factor (VEGF) in astrocytic gliomas--a prognostic factor?. J Neurooncol. 2000; 45(2):117-25. DOI: 10.1023/a:1006333005563. View